News from Target Ovarian Cancer
22.05.13 In the news: Routine cancer risk gene testing announced A research programme that will lay the foundations for anyone with cancer to have access to genetic testing has been launched with £2.7 million funding from the Wellcome Trust.
22.05.13 Avastin too expensive for routine use on the NHS In two separate pieces of final guidance, the National Institute for Health and Care Excellence (NICE) has advised the NHS against funding the drug bevacizumab (Avastin) for advanced ovarian cancer.
21.05.13 Team Crockers raises over £10,000! Congratulations to the wonderful (and brave) Team Crockers who abseiled down the UK's tallest abseil tower at the National Abseil Centre in Northampton, on Saturday 18th May!
20.05.13 Today is International Clinical Trials Day Clinical trials are the essential process for the development of life extending cancer therapies. Target Ovarian Cancer is very aware of the fact that there has been no new life extending treatments for ovarian cancer for over 20 years.